1. Home
  2. TJX vs REGN Comparison

TJX vs REGN Comparison

Compare TJX & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TJX Companies Inc. (The)

TJX

TJX Companies Inc. (The)

N/A

Current Price

$140.39

Market Cap

146.6B

ML Signal

N/A

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

N/A

Current Price

$919.82

Market Cap

84.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TJX
REGN
Founded
1962
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
146.6B
84.3B
IPO Year
1994
1995

Fundamental Metrics

Financial Performance
Metric
TJX
REGN
Price
$140.39
$919.82
Analyst Decision
Buy
Buy
Analyst Count
23
28
Target Price
$165.55
★ $991.00
AVG Volume (30 Days)
★ 5.3M
869.8K
Earning Date
11-18-2026
10-30-2026
Dividend Yield
★ 1.38%
0.41%
EPS Growth
★ 14.32
8.19
EPS
2.55
★ 37.37
Revenue
★ $29,078,407,000.00
$5,872,227,000.00
Revenue This Year
$6.09
$31.18
Revenue Next Year
$6.20
$7.19
P/E Ratio
$54.69
★ $24.71
Revenue Growth
6.04
★ 20.82
52 Week Low
$122.81
$591.52
52 Week High
$170.00
$991.73

Technical Indicators

Market Signals
Indicator
TJX
REGN
Relative Strength Index (RSI) 53.35 57.41
Support Level $122.81 $735.26
Resistance Level $161.43 $986.64
Average True Range (ATR) 4.38 32.57
MACD 0.09 -4.43
Stochastic Oscillator 63.03 32.58

Price Performance

Historical Comparison
TJX
REGN

About TJX TJX Companies Inc. (The)

Founded in 1987, TJX Companies is the world's largest off-price apparel and home fashions retailer, operating more than 5,000 stores across nine countries. In fiscal 2026, the company generated roughly $60 billion in sales. TJX operates through four segments: Marmaxx (61% of sales), HomeGoods (17%), TJX Canada (9%), and TJX international (13%). Its off-price model emphasizes branded merchandise at meaningful discounts, driving high traffic and rapid inventory turnover.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Share on Social Networks: